The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Date: February 11, 2026 Introduction In the first few weeks of 2026, a singular healthcare name has dominated the screens of institutional traders and retail investors alike: DaVita Inc. (NYSE: DVA). Once viewed with skepticism in late 2023 as the "Ozempic era" threatened to upend chronic kidney disease (CKD) management, DaVita has staged a remarkable [...]
DaVita’s fourth quarter results drew a positive market response, as the company outpaced Wall Street expectations on both revenue and non-GAAP profit. Management identified revenue per treatment growth and disciplined execution in its Integrated Kidney Care (IKC) segment as the main contributors to performance, despite a year-over-year decline in operating margin. CEO Javier Rodriguez highlighted the company’s progress in patient outcomes within IKC programs, citing better treatment adherence and reduced hospitalizations. The quarter also saw the impact of higher health benefit costs, which partially offset operational gains.
Shares of dialysis provider DaVita Inc. (NYSE:DVA)
jumped 25.3% in the morning session after the company reported fourth-quarter results that topped Wall Street's expectations and issued a robust earnings forecast for 2026.
Dialysis provider DaVita Inc. (NYSE:DVA) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 9.9% year on year to $3.62 billion. Its non-GAAP profit of $3.40 per share was 6.5% above analysts’ consensus estimates.
